 Continuous intratumoral infusion methotrexate recurrent glioblastoma pilot study patients documented recurrences glioblastoma multiforme continuous infusions methotrexate implantable catheters subcutaneous refillable pumps continuous infusion methotrexate mg/d concomitant oral administration folinic acid methotrexate dose weeks mg/d patients Samples serum ventricular cerebrospinal fluid CSF levels methotrexate total bioactive folates brain tissue patients determination methotrexate concentration patients weeks implantation infusion device clinical examination sequential radiological studies clear evidence reduction tumor size Pneumonia patient mild hepatitis increased seizure frequency Methotrexate stable delivery system days ventricular CSF steady-state levels days Steady-state ventricular CSF levels methotrexate serum levels patients reverse true others Levels total bioactive folates CSF normal range Methotrexate concentrations center tumor measurable amounts methotrexate detectable areas brain autopsy patients variable liquefactive necrosis brain tumors viable tumor periphery tumor bed preliminary results feasible methotrexate brain tumor cavities little central nervous system systemic toxicity patients Better delineation safety efficacy therapeutic approach clinical trials